학술논문

Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study
Document Type
Article
Source
In ESMO Open January 2024 9(1)
Subject
Gastrointestinal Cancers
Language
ISSN
2059-7029